Boyd Haley

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Boyd Eugene Haley
Born (1940-09-22) September 22, 1940 (age 76)
Greensburg, Indiana
Institutions University of Wyoming, University of Kentucky
Alma mater Franklin College, University of Idaho, Washington State University
Thesis Gamma-fluoro-adenosinetriphosphate: I. Synthesis and properties; II. Interaction with myosin, heavy meromyosin, and fumarase. (1971)
Known for Photoaffinity labeling
Notable awards Sigma Xi[1]
Spouse Sandy Haley[2]

Boyd E. Haley (born September 22, 1940, Greensburg, Indiana) is a retired professor of chemistry at the University of Kentucky, known for his involvement with the anti-vaccination movement.[3]

Education and career[edit]

A native of Greensburg, Indiana, Haley graduated from New Point High School there in 1959. He received his bachelor's degree from Franklin College in Franklin, Indiana in 1963, after which he was awarded a teaching fellowship at Howard University.[4] He then served as a U.S. Army medic for a few years, before obtaining his M.S. from the University of Idaho in 1967 and his Ph.D. in chemistry-biochemistry from Washington State University in 1971, after which he served as a postdoctoral scholar at Yale University for three years. Haley has described the research he conducted at WSU thusly: "The guy I worked for at Washington State was a muscle biochemist. We worked together to make chemical modifications on ATP to try to identify how and exactly where ATP binds to cause muscle movement."[5] From 1974 to 1985, he was a professor at the University of Wyoming, before being appointed first a professor of medicinal chemistry at the University of Kentucky, and later, the chairman of the Chemistry department there in 1997.[1]

Research and views[edit]

Further information: Dental amalgam controversy

Haley has been a prominent figure in the anti-vaccination movement.[3]

One of Haley's best-known papers was one which said that levels of glutamine synthetase were considerably higher in the cerebrospinal fluid of patients with Alzheimer's disease than those without.[6][7]

Haley surmises that mercury released from dental amalgams could be a potential cause of autism and Alzheimer's disease. His findings have not been reproduced and the United States Public Health Service and the American Dental Association reject these claims.[8][9]

Haley has also speculated that gold salts may be useful in the treatment of autism.[10]

OSR#1 and FDA Regulations[edit]

Haley is the founder of CTI Science, a Lexington, Kentucky-based biotechnology firm. CTI marketed a product, OSR#1, for human consumption; it was described as an "antioxidant" dietary supplement that is known to be a powerful chelator from a family of chelators originally developed to remove heavy metals from soil and acid mine drainage.[11]

In June 2008, an FDA toxicologist questioned[12] "on what basis the product could be expected to be safe and could be considered a dietary ingredient", but CTI Science and Haley had not responded as of January 2010.[11] The testing was described by Ellen Silbergeld of the Bloomberg School of Public Health as incomplete and indicative of toxicity.[13] On June 17, 2010, the FDA sent a warning letter noting five potential violations, expressing concern over the testing, and requiring a response in 15 days.[14][15] Although Haley wrote an op-ed for the Lexington Herald-Leader,[16][17] the FDA did not receive a formal response and OSR#1 was withdrawn from the market.[18]

References[edit]

  1. ^ a b "Curriculum Vitae" (PDF). Food and Drug Administration. Retrieved 6 August 2013. 
  2. ^ "James "Jim" Haley". Muskogee Phoenix. 4 September 2007. Retrieved 29 August 2013. 
  3. ^ a b Salzberg S (28 June 2010), Another Hero Of The Anti-Vaccine Movement Bites The Dust, Forbes 
  4. ^ "Boyd Eugene Haley". Greensburg Daily News. 13 June 1963. 
  5. ^ Worley, Jeff (25 September 2003). "Boyd Haley: Tagging Toxins for Better Health". University of Kentucky. Retrieved 7 October 2013. 
  6. ^ Gunnersen D, Haley B (December 1992). "Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker". Proc. Natl. Acad. Sci. U.S.A. 89 (24): 11949–53. doi:10.1073/pnas.89.24.11949. PMC 50675Freely accessible. PMID 1361232. 
  7. ^ "A Possible Alzheimer Marker Is Found". The New York Times. 15 December 1992. Retrieved 12 February 2014. 
  8. ^ "Questions and Answers on Dental Amalgam". Food and Drug Administration. 2006-10-30. Archived from the original on 2007-10-19. Retrieved 2008-01-04. 
  9. ^ "ADA Statement on Dental Amalgam". American Dental Association. 2007-04-06. Archived from the original on 2007-10-11. Retrieved 2008-01-04. 
  10. ^ Olmsted, Dan (2005-12-30). "The Age of Autism: Gold standards". United Press International. Archived from the original on 20 March 2008. Retrieved 2008-01-04. 
  11. ^ a b "OSR#1: Industrial chemical or autism treatment?", Chicago Tribune, January 17, 2010
  12. ^ FDA letters and documents
  13. ^ "FDA warns maker of autism supplement". UPI. June 24, 2010. Retrieved September 12, 2011. 
  14. ^ Warning letter CIN-10-107927-14 from US FDA, June 17, 2010
  15. ^ Tsouderos, Trine (June 23, 2010). "FDA warns maker of product used as alternative autism treatment". Chicago Tribune. ISSN 1085-6706. Retrieved September 12, 2011. 
  16. ^ Haley, Boyd (June 26, 2010). "Dietary supplement safe for right use". Lexington Herald-Leader. ISSN 0745-4260. Retrieved September 12, 2011. 
  17. ^ Tsouderos, Trine (July 12, 2010). "Supplement seller says FDA may be 'confused'". Chicago Tribune. ISSN 1085-6706. Retrieved September 12, 2011. 
  18. ^ Tsouderos, Trine (July 26, 2010). "Controversial supplement to come off shelves". Chicago Tribune. ISSN 1085-6706. Retrieved September 12, 2011. 

External links[edit]